FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896082387> ?p ?o ?g. }

• W2896082387 endingPage "1384" @default.
• W2896082387 startingPage "1379" @default.
• W2896082387 abstract "Background Tranexamic acid (TA) is an antifibrinolytic drug currently used systemically to control bleeding. To date, there have been no prospective studies of the effectiveness of inhaled TA for the treatment of hemoptysis. Objectives The goal of this study was to prospectively assess the effectiveness of TA inhalations (ie, nebulized TA) for hemoptysis treatment. Methods This analysis was a double-blind, randomized controlled trial of treatment with nebulized TA (500 mg tid) vs placebo (normal saline) in patients admitted with hemoptysis of various etiologies. Patients with massive hemoptysis (expectorated blood > 200 mL/24 h) and hemodynamic or respiratory instability were excluded. Mortality and hemoptysis recurrence rate were assessed at 30 days and following 1 year. Results Forty-seven patients were randomized to receive TA inhalations (n = 25) or normal saline (n = 22). TA was associated with a significantly reduced expectorated blood volume starting from day 2 of admission. Resolution of hemoptysis within 5 days of admission was observed in more TA-treated patients than in those receiving placebo (96% vs 50%; P < .0005). Mean hospital length of stay was shorter for the TA group (5.7 ± 2.5 days vs 7.8 ± 4.6 days; P = .046), with fewer patients requiring invasive procedures such as interventional bronchoscopy or angiographic embolization to control the bleeding (0% vs 18.2%; P = .041). No side effects were noted in either group throughout the follow-up period. In addition, a reduced recurrence rate was noted at the 1-year follow-up (P = .009). Conclusions TA inhalations can be used safely and effectively to control bleeding in patients with nonmassive hemoptysis. Trial Registry ClinicalTrials.gov; No.: NCT01496196; URL: www.clinicaltrials.gov. Tranexamic acid (TA) is an antifibrinolytic drug currently used systemically to control bleeding. To date, there have been no prospective studies of the effectiveness of inhaled TA for the treatment of hemoptysis. The goal of this study was to prospectively assess the effectiveness of TA inhalations (ie, nebulized TA) for hemoptysis treatment. This analysis was a double-blind, randomized controlled trial of treatment with nebulized TA (500 mg tid) vs placebo (normal saline) in patients admitted with hemoptysis of various etiologies. Patients with massive hemoptysis (expectorated blood > 200 mL/24 h) and hemodynamic or respiratory instability were excluded. Mortality and hemoptysis recurrence rate were assessed at 30 days and following 1 year. Forty-seven patients were randomized to receive TA inhalations (n = 25) or normal saline (n = 22). TA was associated with a significantly reduced expectorated blood volume starting from day 2 of admission. Resolution of hemoptysis within 5 days of admission was observed in more TA-treated patients than in those receiving placebo (96% vs 50%; P < .0005). Mean hospital length of stay was shorter for the TA group (5.7 ± 2.5 days vs 7.8 ± 4.6 days; P = .046), with fewer patients requiring invasive procedures such as interventional bronchoscopy or angiographic embolization to control the bleeding (0% vs 18.2%; P = .041). No side effects were noted in either group throughout the follow-up period. In addition, a reduced recurrence rate was noted at the 1-year follow-up (P = .009). TA inhalations can be used safely and effectively to control bleeding in patients with nonmassive hemoptysis." @default.
• W2896082387 created "2018-10-26" @default.
• W2896082387 creator A5005436600 @default.
• W2896082387 creator A5015016384 @default.
• W2896082387 creator A5045697237 @default.
• W2896082387 creator A5046803053 @default.
• W2896082387 creator A5077958881 @default.
• W2896082387 creator A5089838734 @default.
• W2896082387 date "2018-12-01" @default.
• W2896082387 modified "2023-10-15" @default.
• W2896082387 title "Inhaled Tranexamic Acid for Hemoptysis Treatment" @default.
• W2896082387 cites W1908990742 @default.
• W2896082387 cites W1909684006 @default.
• W2896082387 cites W1976511219 @default.
• W2896082387 cites W1977375151 @default.
• W2896082387 cites W1980755080 @default.
• W2896082387 cites W1984045504 @default.
• W2896082387 cites W2161926095 @default.
• W2896082387 cites W2162921010 @default.
• W2896082387 cites W2324437595 @default.
• W2896082387 cites W2497470799 @default.
• W2896082387 cites W2753302374 @default.
• W2896082387 cites W2777266300 @default.
• W2896082387 cites W2789322837 @default.
• W2896082387 cites W2792975381 @default.
• W2896082387 cites W2804063761 @default.
• W2896082387 doi "https://doi.org/10.1016/j.chest.2018.09.026" @default.
• W2896082387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30321510" @default.
• W2896082387 hasPublicationYear "2018" @default.
• W2896082387 type Work @default.
• W2896082387 sameAs 2896082387 @default.
• W2896082387 citedByCount "83" @default.
• W2896082387 countsByYear W28960823872019 @default.
• W2896082387 countsByYear W28960823872020 @default.
• W2896082387 countsByYear W28960823872021 @default.
• W2896082387 countsByYear W28960823872022 @default.
• W2896082387 countsByYear W28960823872023 @default.
• W2896082387 crossrefType "journal-article" @default.
• W2896082387 hasAuthorship W2896082387A5005436600 @default.
• W2896082387 hasAuthorship W2896082387A5015016384 @default.
• W2896082387 hasAuthorship W2896082387A5045697237 @default.
• W2896082387 hasAuthorship W2896082387A5046803053 @default.
• W2896082387 hasAuthorship W2896082387A5077958881 @default.
• W2896082387 hasAuthorship W2896082387A5089838734 @default.
• W2896082387 hasConcept C141071460 @default.
• W2896082387 hasConcept C142724271 @default.
• W2896082387 hasConcept C188816634 @default.
• W2896082387 hasConcept C204787440 @default.
• W2896082387 hasConcept C27081682 @default.
• W2896082387 hasConcept C2777397205 @default.
• W2896082387 hasConcept C2778996910 @default.
• W2896082387 hasConcept C2779637338 @default.
• W2896082387 hasConcept C2781436528 @default.
• W2896082387 hasConcept C2991743468 @default.
• W2896082387 hasConcept C42219234 @default.
• W2896082387 hasConcept C71924100 @default.
• W2896082387 hasConceptScore W2896082387C141071460 @default.
• W2896082387 hasConceptScore W2896082387C142724271 @default.
• W2896082387 hasConceptScore W2896082387C188816634 @default.
• W2896082387 hasConceptScore W2896082387C204787440 @default.
• W2896082387 hasConceptScore W2896082387C27081682 @default.
• W2896082387 hasConceptScore W2896082387C2777397205 @default.
• W2896082387 hasConceptScore W2896082387C2778996910 @default.
• W2896082387 hasConceptScore W2896082387C2779637338 @default.
• W2896082387 hasConceptScore W2896082387C2781436528 @default.
• W2896082387 hasConceptScore W2896082387C2991743468 @default.
• W2896082387 hasConceptScore W2896082387C42219234 @default.
• W2896082387 hasConceptScore W2896082387C71924100 @default.
• W2896082387 hasIssue "6" @default.
• W2896082387 hasLocation W28960823871 @default.
• W2896082387 hasLocation W28960823872 @default.
• W2896082387 hasOpenAccess W2896082387 @default.
• W2896082387 hasPrimaryLocation W28960823871 @default.
• W2896082387 hasRelatedWork W2001795617 @default.
• W2896082387 hasRelatedWork W2034965507 @default.
• W2896082387 hasRelatedWork W2086483733 @default.
• W2896082387 hasRelatedWork W2091358895 @default.
• W2896082387 hasRelatedWork W2174657578 @default.
• W2896082387 hasRelatedWork W2359529731 @default.
• W2896082387 hasRelatedWork W2993449207 @default.
• W2896082387 hasRelatedWork W3126000190 @default.
• W2896082387 hasRelatedWork W4256399507 @default.
• W2896082387 hasRelatedWork W4380489771 @default.
• W2896082387 hasVolume "154" @default.
• W2896082387 isParatext "false" @default.
• W2896082387 isRetracted "false" @default.
• W2896082387 magId "2896082387" @default.
• W2896082387 workType "article" @default.